SEC Info  
    Home      Search      My Interests      Help      Sign In      Please Sign In

Codexis, Inc. – ‘10-K’ for 12/31/22 – ‘EX-10.8B’

On:  Monday, 2/27/23, at 4:24pm ET   ·   For:  12/31/22   ·   Accession #:  1200375-23-12   ·   File #:  1-34705

Previous ‘10-K’:  ‘10-K’ on 2/28/22 for 12/31/21   ·   Next & Latest:  ‘10-K’ on 2/28/24 for 12/31/23   ·   40 References:   

Find Words in Filings emoji
 
  in    Show  and   Hints

  As Of               Filer                 Filing    For·On·As Docs:Size

 2/27/23  Codexis, Inc.                     10-K       12/31/22  121:15M

Annual Report   —   Form 10-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 10-K        Annual Report                                       HTML   3.22M 
 4: EX-10.19A   Material Contract                                   HTML    366K 
 5: EX-10.19B   Material Contract                                   HTML     35K 
 6: EX-10.19C   Material Contract                                   HTML     35K 
 7: EX-10.22A   Material Contract                                   HTML     97K 
 8: EX-10.22B   Material Contract                                   HTML     81K 
 9: EX-10.23A   Material Contract                                   HTML     99K 
10: EX-10.23B   Material Contract                                   HTML     82K 
 2: EX-10.4     Material Contract                                   HTML     79K 
 3: EX-10.8B    Material Contract                                   HTML     98K 
11: EX-23.1     Consent of Expert or Counsel                        HTML     31K 
12: EX-31.1     Certification -- §302 - SOA'02                      HTML     35K 
13: EX-31.2     Certification -- §302 - SOA'02                      HTML     35K 
14: EX-32.1     Certification -- §906 - SOA'02                      HTML     33K 
20: R1          Cover Page                                          HTML     95K 
21: R2          Audit Information                                   HTML     36K 
22: R3          Consolidated Balance Sheets                         HTML    154K 
23: R4          Consolidated Balance Sheets (Parenthetical)         HTML     54K 
24: R5          Consolidated Statements of Operations               HTML    102K 
25: R6          Consolidated Statements of Operations               HTML     44K 
                (Parenthetical)                                                  
26: R7          Consolidated Statements of Stockholders' Equity     HTML     85K 
27: R8          Consolidated Statements of Stockholders' Equity     HTML     33K 
                (Parenthetical)                                                  
28: R9          Consolidated Statements of Cash Flows               HTML    130K 
29: R10         Consolidated Statements of Cash Flows               HTML     41K 
                (Parenthetical)                                                  
30: R11         Description of Business                             HTML     38K 
31: R12         Basis of Presentation and Summary of Significant    HTML    106K 
                Accounting Policies                                              
32: R13         Revenue Recognition                                 HTML    118K 
33: R14         Net Loss per Share                                  HTML     39K 
34: R15         Collaborative Arrangements                          HTML     72K 
35: R16         Investments in Non-Marketable Securities            HTML     46K 
36: R17         Fair Value Measurements                             HTML     44K 
37: R18         Balance Sheet Details                               HTML     73K 
38: R19         Stock-based Compensation                            HTML    193K 
39: R20         Capital Stock                                       HTML     40K 
40: R21         401(k) Plan                                         HTML     37K 
41: R22         Income Taxes                                        HTML    122K 
42: R23         Commitments and Contingencies                       HTML     93K 
43: R24         Related Party Transactions                          HTML     39K 
44: R25         Segment, Geographical and Other Revenue             HTML    158K 
                Information                                                      
45: R26         Allowance for Credit Losses                         HTML     61K 
46: R27         Restructuring Charges                               HTML     35K 
47: R28         Subsequent Events                                   HTML     33K 
48: R29         Basis of Presentation and Summary of Significant    HTML    158K 
                Accounting Policies (Policies)                                   
49: R30         Basis of Presentation and Summary of Significant    HTML     54K 
                Accounting Policies (Tables)                                     
50: R31         Revenue Recognition (Tables)                        HTML    115K 
51: R32         Net Loss per Share (Tables)                         HTML     37K 
52: R33         Investments in Non-Marketable Securities (Tables)   HTML     41K 
53: R34         Fair Value Measurements (Tables)                    HTML     45K 
54: R35         Balance Sheet Details (Tables)                      HTML     81K 
55: R36         Stock-based Compensation (Tables)                   HTML    187K 
56: R37         Income Taxes (Tables)                               HTML    125K 
57: R38         Commitments and Contingencies (Tables)              HTML     86K 
58: R39         Segment, Geographical and Other Revenue             HTML    162K 
                Information (Tables)                                             
59: R40         Allowance for Credit Losses (Tables)                HTML     62K 
60: R41         Description of Business (Details)                   HTML     33K 
61: R42         Basis of Presentation and Summary of Significant    HTML     68K 
                Accounting Policies - Narrative (Details)                        
62: R43         Basis of Presentation and Summary of Significant    HTML     42K 
                Accounting Policies - Property, Plant, and                       
                Equipment (Details)                                              
63: R44         Revenue Recognition - Disaggregation of Revenue     HTML     63K 
                (Details)                                                        
64: R45         Revenue Recognition - Contracts with Customer       HTML     40K 
                (Details)                                                        
65: R46         Revenue Recognition - Narrative (Details)           HTML     41K 
66: R47         Revenue Recognition - Revenue Recognized (Details)  HTML     45K 
67: R48         Revenue Recognition - Performance Obligation        HTML     60K 
                (Details)                                                        
68: R49         Net Loss per Share (Details)                        HTML     35K 
69: R50         Collaborative Arrangements - GSK Platform           HTML     47K 
                Technology Transfer, Collaboration and License                   
                Agreement (Details)                                              
70: R51         Collaborative Arrangements - Merck Platform         HTML     42K 
                Technology Transfer and License Agreement                        
                (Details)                                                        
71: R52         Collaborative Arrangements - Merck Sitagliptin      HTML     53K 
                Catalyst Supply Agreement (Details)                              
72: R53         Collaborative Arrangements - Enzyme Supply          HTML     36K 
                Agreement (Details)                                              
73: R54         Collaborative Arrangements - Tate & Lyle (Details)  HTML     37K 
74: R55         Collaborative Arrangements - Nestle Global          HTML     49K 
                Development Agreement (Details)                                  
75: R56         Collaborative Arrangements - Porton (Details)       HTML     54K 
76: R57         Collaborative Arrangements - Novartis (Details)     HTML     68K 
77: R58         Collaborative Arrangements - Roche (Details)        HTML     47K 
78: R59         Collaborative Arrangements - Takeda (Details)       HTML     51K 
79: R60         Collaborative Arrangements - Molecular Associates   HTML    113K 
                Inc (Details)                                                    
80: R61         Collaborative Arrangements - Pfizer Enzyme Supply   HTML     60K 
                Agreement (Details)                                              
81: R62         Investments in Non-Marketable Securities -          HTML     60K 
                Narrative (Details)                                              
82: R63         Investments in Non-Marketable Securities -          HTML     44K 
                Carrying Value and Fair Value of Securities                      
                (Details)                                                        
83: R64         Fair Value Measurements (Details)                   HTML     47K 
84: R65         Balance Sheet Details - Cash and Cash Equivalents   HTML     44K 
                (Details)                                                        
85: R66         Balance Sheet Details - Schedule of Inventory       HTML     42K 
                Components (Details)                                             
86: R67         Balance Sheet Details - Property and Equipment,     HTML     55K 
                net (Details)                                                    
87: R68         Balance Sheet Details - Goodwill (Details)          HTML     34K 
88: R69         Balance Sheet Details - Other Accrued Liabilities   HTML     40K 
                (Details)                                                        
89: R70         Stock-based Compensation - Narrative (Details)      HTML    148K 
90: R71         Stock-based Compensation - Stock-Based              HTML     49K 
                Compensation Expense (Details)                                   
91: R72         Stock-based Compensation - Assumptions Used         HTML     49K 
                (Details)                                                        
92: R73         Stock-based Compensation - Option Activity          HTML     82K 
                (Details)                                                        
93: R74         Stock-based Compensation - Award Activity           HTML    107K 
                (Details)                                                        
94: R75         Capital Stock (Details)                             HTML     65K 
95: R76         401(k) Plan (Details)                               HTML     33K 
96: R77         Income Taxes - Components of Loss Before Provision  HTML     41K 
                for Income Taxes (Details)                                       
97: R78         Income Taxes - Components of Provision for Income   HTML     51K 
                Taxes (Details)                                                  
98: R79         Income Taxes - Tax Rate Reconciliation (Details)    HTML     53K 
99: R80         Income Taxes - Components of Deferred Tax Assets    HTML     75K 
                and Liabilities (Details)                                        
100: R81         Income Taxes - Narrative (Details)                  HTML     44K  
101: R82         Income Taxes - NOL Carryforwards and Federal        HTML     41K  
                Research and Development Tax Credits (Details)                   
102: R83         Income Taxes - Reconciliation of Unrecognized Tax   HTML     41K  
                Benefits (Details)                                               
103: R84         Commitments and Contingencies - Narrative           HTML     85K  
                (Details)                                                        
104: R85         Commitments and Contingencies - Lease Costs         HTML     47K  
                (Details)                                                        
105: R86         Commitments and Contingencies - Other Lease         HTML     51K  
                Information (Details)                                            
106: R87         Commitments and Contingencies - Maturity Analysis   HTML     54K  
                of Operating Lease (Details)                                     
107: R88         Commitments and Contingencies - Other Commitments   HTML     42K  
                (Details)                                                        
108: R89         Related Party Transactions (Details)                HTML     88K  
109: R90         Segment, Geographical and Other Revenue             HTML     35K  
                Information - Narrative (Details)                                
110: R91         Segment, Geographical and Other Revenue             HTML     98K  
                Information - Segment Reporting (Details)                        
111: R92         Segment, Geographical and Other Revenue             HTML     48K  
                Information - Concentration Risk (Details)                       
112: R93         Segment, Geographical and Other Revenue             HTML     50K  
                Information - Revenues (Details)                                 
113: R94         Segment, Geographical and Other Revenue             HTML     43K  
                Information - Goodwill (Details)                                 
114: R95         Allowance for Credit Losses - Analysis of           HTML     40K  
                Allowance for Credit Losses (Details)                            
115: R96         Allowance for Credit Losses - Summary of Accounts   HTML     45K  
                Receivable by Aging Category (Details)                           
116: R97         Restructuring Charges (Details)                     HTML     41K  
119: XML         IDEA XML File -- Filing Summary                      XML    213K  
117: XML         XBRL Instance -- cdxs-20221231_htm                   XML   3.46M  
118: EXCEL       IDEA Workbook of Financial Reports                  XLSX    238K  
16: EX-101.CAL  XBRL Calculations -- cdxs-20221231_cal               XML    226K 
17: EX-101.DEF  XBRL Definitions -- cdxs-20221231_def                XML   1.14M 
18: EX-101.LAB  XBRL Labels -- cdxs-20221231_lab                     XML   2.24M 
19: EX-101.PRE  XBRL Presentations -- cdxs-20221231_pre              XML   1.55M 
15: EX-101.SCH  XBRL Schema -- cdxs-20221231                         XSD    238K 
120: JSON        XBRL Instance as JSON Data -- MetaLinks              577±   896K  
121: ZIP         XBRL Zipped Folder -- 0001200375-23-000012-xbrl      Zip   1.08M  


‘EX-10.8B’   —   Material Contract


This Exhibit is an HTML Document rendered as filed.  [ Alternative Formats ]



 <!   C:   C: 
  Document  

    TRANSITION AND SEPARATION AGREEMENT

    This Transition and Separation Agreement (the “Agreement”) by and between Ross Taylor (“Executive”) and Codexis, Inc., a Delaware corporation (the “Company”), is made effective as of the eighth day following the date Executive signs this Agreement (the “Effective Date”) with reference to the following facts:

A.     Executive’s employment with the Company will end as of the Termination Date (as defined below);

B.    Executive and the Company are parties to that certain Change of Control Severance Agreement (the “Change of Control Agreement”);

C.     Executive has agreed to continue to serve as the Company’s Senior Vice President and Chief Financial Officer through the date the Company appoints a new Chief Financial Officer; and    

D.    Executive and the Company want to end their relationship amicably and also to establish the obligations of the parties including, without limitation, all amounts due and owing to Executive.

    NOW, THEREFORE, in consideration of the mutual covenants and agreements hereinafter set forth, the parties agree as follows:

1.Termination Date. Executive and the Company acknowledge and agree that Executive’s status as an employee of the Company shall continue through the earliest of (a) March 6, 2023 (the “Planned Termination Date”), (b) the date the Company terminates Executive’s employment with the Company for other than Cause (as defined in the Change of Control Agreement) (together with the Planned Terminate Date, a “Covered Termination Date”), (c) the date the Company terminates Executive’s employment for Cause or (d) the date Executive voluntarily terminates Executive’s employment (the earliest such date, the “Termination Date”). Executive further acknowledges and agrees that Executive’s status as an officer of the Company and of each of its affiliates, shall end effective as of the earlier of the Termination Date. Executive hereby agrees to execute such further document(s) as shall be determined by the Company as necessary or desirable to give effect to the termination of Executive’s status as an officer of the Company and each of its affiliates as of such earlier date; provided that such documents shall not be inconsistent with any of the terms of this Agreement.
2.Chief Financial Officer Employment.
(a)Chief Financial Officer Employment Period; Duties. During the period (the “Chief Financial Officer Employment Period”) commencing on the date hereof and ending on the earlier of (i) the date the Company appoints a new interim or permanent Chief Financial Officer or (ii) the Termination Date (such earlier date, the “Chief Financial Officer Service End Date”), Executive shall continue to be employed by the Company as the Company’s Senior Vice President and Chief Financial Officer reporting to the Company’s Chief Executive Officer (“CEO”) and shall perform such duties as are customarily associated with such positions and such other duties as are assigned to Executive by the CEO. During the Chief Financial Officer Employment Period, Executive shall devote Executive’s best efforts and substantially all of Executive’s business time and attention to the business of the Company. On the Chief Financial Officer Service End Date, Executive shall cease to serve as an officer of the Company and each of its subsidiaries. Executive agrees to execute such further documents as determined necessary or appropriate by the Company to evidence such cessation of officer status.
(b)Advisor Employment Period; Duties. In the event the Chief Financial Officer Service End Date occurs prior to the Termination Date, then during the period (the “Advisor Employment Period” and, together with the Chief Financial Officer Employment



Period, the “Continued Employment Period”) commencing on the Chief Financial Officer Service End Date and ending on the Termination Date, Executive shall continue to be employed as an advisor to the CEO and shall perform such duties as are requested by the CEO. During the Advisor Employment Period, Executive shall devote Executive’s best efforts and such amount of Executive’s business time and attention as reasonably necessary to fulfill such duties to the business of the Company.
(c)Salary and Benefits Continuation. During the Continued Employment Period, Executive will continue to be paid base salary at the rate in effect on the date of this Agreement in accordance with the Company’s regular payroll procedures, accrue paid vacation, be eligible for all employee benefit plans available to senior executives of the Company and continue to vest into outstanding equity awards, in each case, in accordance with their terms. All payments made to Executive during the Continued Employment Period will be subject to required withholding taxes and authorized deductions.
(d)Protection of Information. Executive reaffirms Executive’s commitment to remain in compliance with that certain Confidential Information and Inventions Assignment Agreement entered into between Executive and the Company (the “Confidentiality Agreement”). Without limiting the foregoing, Executive acknowledges and agrees that, during the Continued Employment Period, Executive shall not, directly or indirectly, become employed by or provide assistance to any competitor of the Company.
3.Final Paycheck; Payment of Accrued Wages and Expenses.
(a)Final Paycheck. As soon as administratively practicable on or after the Termination Date, the Company will pay Executive all accrued but unpaid wages and accrued and unused vacation earned through the Termination Date, subject to standard payroll deductions and withholdings. Executive is entitled to retain these payments regardless of whether Executive executes this Agreement.
(b)Business Expenses. The Company shall reimburse Executive for all outstanding, unreimbursed expenses incurred prior to the Termination Date which are consistent with the Company’s policies in effect from time to time with respect to travel, entertainment and other business expenses, subject to the Company’s requirements with respect to reporting and documenting such expenses. Executive is entitled to these reimbursements regardless of whether Executive executes this Agreement.
(c)Unvested Equity Awards. Executive acknowledges that on the Termination Date, the unvested portion of each outstanding equity award (after giving effect to any accelerated vesting provided under Section 4 of this Agreement), including, without limitation, the unvested portion of each stock option, restricted stock unit award and performance stock unit award held by Executive will be automatically terminated without payment of any consideration therefor.
4.Separation Benefits. Without admission of any liability, fact or claim, the Company hereby agrees, subject to the execution of this Agreement and the delivery to the Company of a copy of the General Release of Claims attached hereto as Exhibit A (the “Release of Claims”) signed on or after the Termination Date that becomes effective and irrevocable within thirty days following the Termination Date, and further subject to Executive remaining employed hereunder through the Covered Termination Date and continued compliance with the terms and conditions of the Confidentiality Agreement, to provide Executive the severance benefits set forth below. For the avoidance of doubt, in the event the Company terminates Executive’s employment for other than Cause or Executive terminates Executive’s employment with the Company before the Covered Termination Date, then Executive shall be entitled to the Separation Payments and Benefits described in this Section 4. Specifically, the Company and Executive agree as follows:
(a)Cash Severance. On the first payroll date that is at least five (5) business days following the date the Release of Claims becomes effective and irrevocable,
2





the Company shall pay to Executive an amount equal to twelve (12) months of Executive’s base salary, subject to continuing compliance by Executive with the terms hereof. Such payment shall be made in a single cash lump sum, subject to withholding taxes and authorized deductions.
(b)Annual Bonus. Executive shall be paid an amount equal to $185,725, which represents 85% of Executive’s target annual bonus for fiscal year 2022 and shall be paid in full satisfaction thereof, irrespective of the Company’s or Executive’s performance. Such payment shall be made in a single cash lump sum, subject to withholding taxes and authorized deductions.
(c)Restricted Stock Units and Performance Stock Units. To the extent the Covered Termination Date occurs prior to March 6, 2023, then the vesting of any restricted stock units and performance stock units scheduled to vest on or prior to March 6, 2023 shall be accelerated as of immediately prior to the Covered Termination Date. The shares of Company common stock underlying any restricted stock units and performance stock units for which vesting is accelerated pursuant to the preceding sentence shall be issued in accordance with the agreement evidencing such restricted and performance stock units.
(d)Continued Healthcare. If Executive elects to receive continued healthcare coverage pursuant to the provisions of the Consolidated Omnibus Budget Reconciliation Act of 1985, as amended (“COBRA”), the Company shall directly pay, or reimburse Executive for, the premium for Executive and Executive’s covered dependents from the Termination Date through the earlier of (i) the twelve (12) month anniversary of the Termination Date and (ii) the date Executive, Executive’s covered dependents, if any, become eligible for healthcare coverage under another employer’s plan(s), provided, however, that if (1) any plan pursuant to which such benefits are provided is not, or ceases prior to the expiration of the continuation coverage period to be, exempt from the application of Section 409A of the Internal Revenue Code of 1986, as amended (the “Code”) under Treasury Regulation Section 1.409A-1(a)(5), (2) the Company is otherwise unable to continue to cover Executive or Executive’s dependents under its group health plans, or (3) the Company cannot provide the benefit without violating applicable law (including, without limitation, Section 2716 of the Public Health Service Act), then, in any such case, an amount equal to each remaining Company subsidy shall thereafter be paid to Executive in substantially equal monthly installments over the remaining period the Company would otherwise directly pay or reimburse Executive. After the Company ceases to pay premiums pursuant to the preceding sentence, Executive may, if eligible, elect to continue healthcare coverage at Executive’s expense in accordance with the provisions of COBRA.
(e)Taxes. Executive understands and agrees that all benefits under this Agreement will be subject to appropriate tax withholding and other deductions. To the extent any taxes may be payable by Executive for the benefits provided to Executive by this Agreement beyond those withheld by the Company, Executive agrees to pay them and to indemnify and hold the Company and the other entities released herein harmless for any tax claims or penalties, and associated attorneys’ fees and costs, resulting from any failure by Executive to make required payments.
(f)Sole Separation Benefit. Executive agrees that the benefits provided by this Section 4 are not required under the Company’s normal policies and procedures and are provided as a severance solely in connection with this Agreement. Executive acknowledges and agrees that the benefits referenced in this Section 4 constitute adequate and valuable consideration, in and of themselves, for the promises contained in this Agreement.
5.Full Payment. Executive acknowledges that the payment and arrangements herein shall constitute full and complete satisfaction of any and all amounts properly due and owing to Executive as a result of Executive’s employment with the Company and the termination thereof. Executive further acknowledges that, other than the Confidentiality Agreement, agreements
3





evidencing Executive’s equity awards (as modified under Section 4(c) hereof) and as explicitly set forth in Section 11 hereof, this Agreement shall supersede each agreement entered into between Executive and the Company regarding Executive’s employment, including, without limitation, the offer letter entered into between the Company and Executive as of August 4, 2019, the Change of Control Agreement and any other employment agreement, bonus plan or arrangement, severance and/or change in control agreement, and each such agreement shall be deemed terminated and of no further effect as of the Effective Date.
6.Executive’s Release of the Company. Executive understands that by agreeing to the release provided by this Section 6, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its directors, officers, employees, investors or other agents for any reason whatsoever based on anything that is the subject of this release and that has occurred as of the date Executive signs this Agreement.
(a)Released Claims. On behalf of Executive and Executive’s heirs, assigns, executors, administrators, trusts, spouse and estate, Executive hereby releases and forever discharges the “Releasees” hereunder, consisting of the Company and each of its owners, affiliates, subsidiaries, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which Executive now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive’s hire, employment, remuneration or termination by the Releasees, or any of them, Claims arising under federal, state, or local laws relating to employment, Claims of any kind that may be brought in any court or administrative agency, including any Claims arising under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §  2000, et seq.; Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621, et seq.; Civil Rights Act of 1866, and Civil Rights Act of 1991; 42 U.S.C. § 1981, et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; The Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C.  § 2101 et seq.; the California Fair Employment and Housing Act, as amended, Cal. Lab. Code § 12940 et seq.; the California Equal Pay Law, as amended, Cal. Lab. Code §§ 1197.5(a),199.5; the Moore-Brown-Roberti Family Rights Act of 1991, as amended, Cal. Gov’t Code §§12945.2, 19702.3; California Labor Code §§ 1101, 1102; the California WARN Act, California Labor Code §§ 1400 et. seq; California Labor Code §§ 1102.5(a),(b); Claims for wages under the California Labor Code and any other federal, state or local laws of similar effect; the employment and civil rights laws of California; Claims for breach of implied or express contract; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, libel, slander, defamation, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of good faith and fair dealing; and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees.
(b)Unreleased Claims. Notwithstanding the generality of the foregoing, Executive does not release the following claims:
(i)Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;
4





(ii)Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;
(iii)Claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA;
(iv)Claims to accrued but unpaid base salary or any benefit entitlements vested as the date Executive signs this Agreement, pursuant to written terms of any Company or affiliate employee benefit plan, program, or policy, including to vested equity awards;
(v)Claims for indemnification under any indemnification agreement, the Company’s Bylaws or other organizational documents, applicable directors’ and officers’ insurance coverage, or any applicable law;
(vi)Executive’s right to enforce the terms of this Agreement; and
(vii)Executive’s right to bring to the attention of the Equal Employment Opportunity Commission claims of discrimination; provided, however, that Executive does release Executive’s right to secure any damages for alleged discriminatory treatment.
(c)Acknowledgement. In accordance with the Older Workers Benefit Protection Act of 1990, Executive has been advised of the following:
(i)Executive should consult with an attorney before signing this Agreement;
(ii)Executive has been given at least twenty-one (21) days to consider this Agreement; and
(iii)Executive has seven (7) days after signing this Agreement to revoke it. If Executive wishes to revoke this Agreement, Executive must deliver notice of Executive’s revocation in writing, no later than 5:00 p.m. on the 7th day following Executive’s execution of this Agreement to Karen Frechou-Armijo at karen.armijo@codexis.com. Executive understands that if Executive revokes this Agreement, it will be null and void in its entirety, and Executive will not be entitled to any payments or benefits provided in this Agreement that are not otherwise required by applicable law.
(d)EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS WHICH THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
5





7.Non-Disparagement, Transition and Transfer of Company Property. Executive further agrees that:
(a)Non-Disparagement. Executive agrees that Executive shall not disparage, criticize or defame the Company, its affiliates and their respective affiliates, directors, officers, agents, partners, stockholders, employees, products, services, technology or business, either publicly or privately. The Company agrees that it shall not, and shall instruct its officers and directors to not, disparage, criticize or defame Executive, either publicly or privately. Nothing in this Section 7(a) shall have application to any evidence or testimony required by any court, arbitrator or government agency.
(b)Transition. Each of the Company and Executive shall use their respective reasonable efforts to cooperate with each other in good faith to facilitate a smooth transition of Executive’s duties to other executive(s) of the Company, including but not limited to assisting in the filing of the upcoming Form 10-K.
(c)Transfer of Company Property. On or before the Termination Date, Executive shall turn over to the Company all files, memoranda, records, and other documents, and any other physical or personal property which are the property of the Company and which Executive had in Executive’s possession, custody or control at the time Executive signed this Agreement.
8.Executive Representations. Executive warrants and represents that (a) Executive has not filed or authorized the filing of any complaints, charges or lawsuits against the Company or any affiliate of the Company with any governmental agency or court, and that if, unbeknownst to Executive, such a complaint, charge or lawsuit has been filed on Executive’s behalf, Executive will immediately cause it to be withdrawn and dismissed, (b) Executive has reported all hours worked as of the date of this Agreement and has been paid all compensation, wages, bonuses, commissions, and/or benefits to which Executive may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to Executive, except as provided in this Agreement, (c) Executive has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act or any similar state law, (d) the execution, delivery and performance of this Agreement by Executive does not and will not conflict with, breach, violate or cause a default under any agreement, contract or instrument to which Executive is a party or any judgment, order or decree to which Executive is subject, and (e) upon the execution and delivery of this Agreement by the Company and Executive, this Agreement will be a valid and binding obligation of Executive, enforceable in accordance with its terms.
9.No Assignment by Executive. Executive warrants and represents that no portion of any of the matters released herein, and no portion of any recovery or settlement to which Executive might be entitled, has been assigned or transferred to any other person, firm or corporation not a party to this Agreement, in any manner, including by way of subrogation or operation of law or otherwise. If any claim, action, demand or suit should be made or instituted against the Company or any other Releasee because of any actual assignment, subrogation or transfer by Executive, Executive agrees to indemnify and hold harmless the Company and all other Releasees against such claim, action, suit or demand, including necessary expenses of investigation, attorneys’ fees and costs. In the event of Executive’s death, this Agreement shall inure to the benefit of Executive and Executive’s executors, administrators, heirs, distributees, devisees, and legatees. None of Executive’s rights or obligations may be assigned or transferred by Executive, other than Executive’s rights to payments hereunder, which may be transferred only upon Executive’s death by will or operation of law.
10.Governing Law. This Agreement shall be construed and enforced in accordance with, and the rights of the parties shall be governed by, the laws of the State of California or, where applicable, United States federal law, in each case, without regard to any conflicts of laws provisions or those of any state other than California.
11.Miscellaneous. Executive acknowledges that there are no other agreements, written, oral or implied, and that Executive may not rely on any prior negotiations, discussions,
6





representations or agreements. This Agreement may be modified only in writing, and such writing must be signed by both parties and recited that it is intended to modify this Agreement. This Agreement may be executed in separate counterparts, each of which is deemed to be an original and all of which taken together constitute one and the same agreement.
12.Company Assignment and Successors. The Company shall assign its rights and obligations under this Agreement to any successor to all or substantially all of the business or the assets of the Company (by merger or otherwise). This Agreement shall be binding upon and inure to the benefit of the Company and its successors, assigns, personnel and legal representatives.
13.Maintaining Confidential Information. Executive reaffirms Executive’s obligations under the Confidentiality Agreement. For the avoidance of doubt, nothing in this Agreement or the Confidentiality Agreement will be construed to prohibit Executive from filing a charge with, reporting possible violations to, or participating or cooperating with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making other disclosures that are protected under the whistleblower, anti-discrimination, or anti-retaliation provisions of federal, state or local law or regulation; provided, however, that Executive may not disclose information of the Company or any of their affiliates that is protected by the attorney-client privilege, except as otherwise required by law. Executive does not need the prior authorization of the Company to make any such reports or disclosures, and Executive is not required to notify the Company that Executive has made such reports or disclosures. Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in the Confidentiality Agreement or this Agreement: (i) Executive will not be in breach of the Confidentiality Agreement or this Agreement, and will not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.
14.Executive’s Cooperation.  After the Termination Date, Executive shall cooperate with the Company and its affiliates, upon the Company’s reasonable request, with respect to any internal investigation or administrative, regulatory or judicial proceeding involving matters within the scope of Executive’s duties and responsibilities to the Company or its affiliates during Executive’s employment with the Company (including, without limitation, Executive being available to the Company upon reasonable notice for interviews and factual investigations, appearing at the Company’s reasonable request to give testimony without requiring service of a subpoena or other legal process, and turning over to the Company all relevant Company documents which are or may have come into Executive’s possession during Executive’s employment); provided, however, that (i) any such request by the Company shall not be unduly burdensome or interfere with Executive’s personal schedule or ability to engage in gainful employment and (ii) this provision shall not apply to any such investigation or proceeding that arises out of or relates to a dispute between Executive and the Company and/or any of its affiliates or if Executive’s reasonable interests are adverse to the Company or its affiliates in any such investigation or proceeding. The Company agrees to promptly pay or reimburse Executive upon demand for all of Executive’s reasonable travel and other direct expenses reasonably incurred, or to be reasonably incurred, to comply with Executive’s obligations under this Section 14. 
(Signature page(s) follow)
7





    IN WITNESS WHEREOF, the undersigned have caused this Transition and Separation Agreement to be duly executed and delivered as of the date indicated next to their respective signatures below.



DATED: ________________, 2023
                        __________________________________
                        Ross Taylor


                        CODEXIS, INC.
DATED: ________________, 2023


                        By: _______________________________
    Name:
    Title:

[Signature page to Codexis, Inc. - Transition and Separation Agreement]







|


EXHIBIT A

GENERAL RELEASE OF CLAIMS

This General Release of Claims (“Release”) is entered into as of _________________, 2023, between Ross Taylor (“Executive”) and Codexis, Inc., a Delaware corporation (the “Company” and, together with Executive, the “Parties”), effective as of the eighth (8th) day after the date of Executive’s signature hereto.

1.Executive’s Release of the Company. Executive understands that by agreeing to this Release, Executive is agreeing not to sue, or otherwise file any claim against, the Company or any of its directors, officers, employees, investors or other agents for any reason whatsoever based on anything that has occurred in connection with Executive’s employment or other relationship with the Company and the conclusion of that employment or other relationship that the Company as of the date Executive signs this Release.
(a)On behalf of Executive and Executive’s heirs, assigns, executors, administrators, trusts, spouse and estate, Executive hereby releases and forever discharges the “Releasees” hereunder, consisting of the Company and each of its owners, affiliates, subsidiaries, predecessors, successors, assigns, agents, directors, officers, partners, employees, and insurers, and all persons acting by, through, under or in concert with them, or any of them, of and from any and all manner of action or actions, cause or causes of action, in law or in equity, suits, debts, liens, contracts, agreements, promises, liability, claims, demands, damages, loss, cost or expense, of any nature whatsoever, known or unknown, fixed or contingent (hereinafter called “Claims”), which Executive now has or may hereafter have against the Releasees, or any of them, by reason of any matter, cause, or thing whatsoever from the beginning of time to the date hereof, including, without limiting the generality of the foregoing, any Claims arising out of, based upon, or relating to Executive’s hire, employment, remuneration or resignation by the Releasees, or any of them, Claims arising under federal, state, or local laws relating to employment, Claims of any kind that may be brought in any court or administrative agency, including any Claims arising under Title VII of the Civil Rights Act of 1964, as amended, 42 U.S.C. §  2000, et seq.; Americans with Disabilities Act, as amended, 42 U.S.C. § 12101 et seq.; the Rehabilitation Act of 1973, as amended, 29 U.S.C. § 701 et seq.; the Age Discrimination in Employment Act, as amended, 29 U.S.C. § 621, et seq.; Civil Rights Act of 1866, and Civil Rights Act of 1991; 42 U.S.C. § 1981, et seq.; Equal Pay Act, as amended, 29 U.S.C. § 206(d); regulations of the Office of Federal Contract Compliance, 41 C.F.R. Section 60, et seq.; the Family and Medical Leave Act, as amended, 29 U.S.C. § 2601 et seq.; the Fair Labor Standards Act of 1938, as amended, 29 U.S.C. § 201 et seq.; the Employee Retirement Income Security Act, as amended, 29 U.S.C. § 1001 et seq.; the Worker Adjustment and Retraining Notification Act, as amended, 29 U.S.C.  § 2101 et seq.; the California Fair Employment and Housing Act, as amended, Cal. Lab. Code § 12940 et seq.; the California Equal Pay Law, as amended, Cal. Lab. Code §§ 1197.5(a),199.5; the Moore-Brown-Roberti Family Rights Act of 1991, as amended, Cal. Gov’t Code §§12945.2, 19702.3; California Labor Code §§ 1101, 1102; the California WARN Act, California Labor Code §§ 1400 et. seq; California Labor Code §§ 1102.5(a),(b); Claims for wages under the California Labor Code and any other federal, state or local laws of similar effect; the employment and civil rights laws of California; Claims for breach of contract; Claims arising in tort, including, without limitation, Claims of wrongful dismissal or discharge, discrimination, harassment, retaliation, fraud, misrepresentation, defamation, defamation, infliction of emotional distress, violation of public policy, and/or breach of the implied covenant of good faith and fair dealing; and Claims for damages or other remedies of any sort, including, without limitation, compensatory damages, punitive damages, injunctive relief and attorney’s fees.
(b)Notwithstanding the generality of the foregoing, Executive does not release the following claims:
A-1




(i)Claims to enforce Executive’s rights under the Transition and Separation Agreement entered into between the Company and Executive on [________], 2023 (the “Transition and Separation Agreement”).
(ii)Claims for unemployment compensation or any state disability insurance benefits pursuant to the terms of applicable state law;
(iii)Claims for workers’ compensation insurance benefits under the terms of any worker’s compensation insurance policy or fund of the Company;
(iv)Claims to continued participation in certain of the Company’s group benefit plans pursuant to the terms and conditions of COBRA;
(v)Claims to any benefit entitlements vested as the date of Executive’s employment termination, pursuant to written terms of any Company or affiliate employee benefit plan, program or policy;
(vi)Claims for indemnification under the Company’s Bylaws, California Labor Code Section 2802 or any other applicable law; and
(vii)Executive’s right to bring to the attention of the Equal Employment Opportunity Commission claims of discrimination; provided, however, that Executive does release Executive’s right to secure any damages for alleged discriminatory treatment.
(c)Acknowledgement. In accordance with the Older Workers Benefit Protection Act of 1990, Executive has been advised of the following:
(i)Executive should consult with an attorney before signing this Release;
(ii)Executive has been given at least twenty-one (21) days to consider this Release; and
(iii)Executive has seven (7) days after signing this Release to revoke it. If Executive wishes to revoke this Release, Executive must deliver notice of Executive’s revocation in writing, no later than 5:00 p.m. on the 7th day following Executive’s execution of this Release to Karen Frechou-Armijo at karen.armijo@codexis.com. Executive understands that if Executive revokes this Release, it will be null and void in its entirety, and Executive will not be entitled to any payments or benefits provided in the Transition and Separation Agreement, other than as provided in Sections 2 and 3 thereof.
(d)EXECUTIVE ACKNOWLEDGES THAT EXECUTIVE HAS BEEN ADVISED OF AND IS FAMILIAR WITH THE PROVISIONS OF CALIFORNIA CIVIL CODE SECTION 1542, WHICH PROVIDES AS FOLLOWS:
“A GENERAL RELEASE DOES NOT EXTEND TO CLAIMS THAT THE CREDITOR OR RELEASING PARTY DOES NOT KNOW OR SUSPECT TO EXIST IN HIS OR HER FAVOR AT THE TIME OF EXECUTING THE RELEASE AND THAT, IF KNOWN BY HIM OR HER, WOULD HAVE MATERIALLY AFFECTED HIS OR HER SETTLEMENT WITH THE DEBTOR OR RELEASED PARTY.”
BEING AWARE OF SAID CODE SECTION, EXECUTIVE HEREBY EXPRESSLY WAIVES ANY RIGHTS EXECUTIVE MAY HAVE THEREUNDER, AS WELL AS UNDER ANY OTHER STATUTES OR COMMON LAW PRINCIPLES OF SIMILAR EFFECT.
A-2




2.Executive Representations. Executive warrants and represents that (a) Executive has not filed or authorized the filing of any complaints, charges or lawsuits against the Company or any of its affiliates with any governmental agency or court, and that if, unbeknownst to Executive, such a complaint, charge or lawsuit has been filed on Executive’s behalf, Executive will immediately cause it to be withdrawn and dismissed, (b) Executive has been paid all compensation, wages, bonuses, commissions, and/or benefits to which Executive may be entitled and no other compensation, wages, bonuses, commissions and/or benefits are due to Executive, except as provided in Sections 2 and 3 of the Transition and Separation Agreement, (c) Executive has no known workplace injuries or occupational diseases and has been provided and/or has not been denied any leave requested under the Family and Medical Leave Act or any similar state law, (d) the execution, delivery and performance of this Release by Executive does not and will not conflict with, breach, violate or cause a default under any agreement, contract or instrument to which Executive is a party or any judgment, order or decree to which Executive is subject, and (e) upon the execution and delivery of this Release by the Company and Executive, this Release will be a valid and binding obligation of Executive, enforceable in accordance with its terms.
3.Maintaining Confidential Information. Executive reaffirms Executive’s obligations under the Confidentiality Agreement (as defined in the Transition and Separation Agreement). Executive acknowledges and agrees that the payments provided in Section 3 of the Transition and Separation Agreement shall be subject to Executive’s continued compliance with Executive’s obligations under the Confidentiality Agreement. For the avoidance of doubt, nothing in this Release, the Transition and Separation Agreement or the Confidentiality Agreement will be construed to prohibit Executive from filing a charge with, reporting possible violations to, or participating or cooperating with any governmental agency or entity, including but not limited to the EEOC, the Department of Justice, the Securities and Exchange Commission, Congress, or any agency Inspector General, or making other disclosures that are protected under the whistleblower, anti-discrimination, or anti-retaliation provisions of federal, state or local law or regulation; provided, however, that Executive may not disclose information of the Company or any of their affiliates that is protected by the attorney-client privilege, except as otherwise required by law. Executive does not need the prior authorization of the Company to make any such reports or disclosures, and Executive is not required to notify the Company that Executive has made such reports or disclosures. Furthermore, in accordance with 18 U.S.C. § 1833, notwithstanding anything to the contrary in the Confidentiality Agreement, this Release or the Transition and Separation Agreement: (i) Executive will not be in breach of the Confidentiality Agreement, this Release or the Transition and Separation Agreement, and will not be held criminally or civilly liable under any federal or state trade secret law (x) for the disclosure of a trade secret that is made in confidence to a federal, state, or local government official or to an attorney solely for the purpose of reporting or investigating a suspected violation of law, or (y) for the disclosure of a trade secret that is made in a complaint or other document filed in a lawsuit or other proceeding, if such filing is made under seal; and (ii) if Executive files a lawsuit for retaliation by the Company for reporting a suspected violation of law, Executive may disclose the trade secret to Executive’s attorney, and may use the trade secret information in the court proceeding, if Executive files any document containing the trade secret under seal, and does not disclose the trade secret, except pursuant to court order.
4.Cooperation With the Company. Executive reaffirms Executive’s obligations to cooperate with the Company pursuant to Section 14 of the Transition and Separation Agreement.
5.Severability. The provisions of this Release are severable. If any provision is held to be invalid or unenforceable, it shall not affect the validity or enforceability of any other provision.
6.Choice of Law. This Release shall in all respects be governed and construed in accordance with the laws of the State of California, including all matters of construction, validity and performance, without regard to conflicts of law principles.
7.Integration Clause. This Release, the Transition and Separation Agreement and the Confidentiality Agreement contain the Parties’ entire agreement with regard to the transition and separation of Executive’s employment, and supersede and replace any prior
A-3




agreements as to those matters, whether oral or written, including the Offer Letter (as defined in the Transition and Separation Agreement). This Release may not be changed or modified, in whole or in part, except by an instrument in writing signed by Executive and the Chief Executive Officer of the Company.
8.Execution in Counterparts. This Release may be executed in counterparts with the same force and effectiveness as though executed in a single document. Facsimile signatures shall have the same force and effectiveness as original signatures.
9.Intent to be Bound. The Parties have carefully read this Release in its entirety; fully understand and agree to its terms and provisions; and intend and agree that it is final and binding on all Parties.



(Signature page(s) follow)


A-4




    IN WITNESS WHEREOF, and intending to be legally bound, the Parties have executed the foregoing on the dates shown below.

DATED: _______________, 2023
                        __________________________________
                        Ross Taylor


DATED: _______________, 2023


                        By: _______________________________
        
        

A-5



Dates Referenced Herein   and   Documents Incorporated by Reference

This ‘10-K’ Filing    Date    Other Filings
3/6/23
Filed on:2/27/234,  POSASR
For Period end:12/31/22
8/4/19
 List all Filings 


4 Subsequent Filings that Reference this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/28/24  Codexis, Inc.                     10-K       12/31/23  121:13M
 8/03/23  Codexis, Inc.                     S-8         8/03/23    4:98K                                    Donnelley … Solutions/FA
 8/03/23  Codexis, Inc.                     S-8         8/03/23    4:99K                                    Donnelley … Solutions/FA
 2/28/23  Codexis, Inc.                     POS AM                 3:447K                                   Donnelley … Solutions/FA


36 Previous Filings that this Filing References

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 1/09/23  Codexis, Inc.                     S-8         1/09/23    7:328K                                   Donnelley … Solutions/FA
11/04/22  Codexis, Inc.                     10-Q        9/30/22   86:9.5M
 8/05/22  Codexis, Inc.                     10-Q        6/30/22   83:10M
 2/28/22  Codexis, Inc.                     10-K       12/31/21  111:16M
11/05/21  Codexis, Inc.                     10-Q        9/30/21   84:8.8M
 5/07/21  Codexis, Inc.                     10-Q        3/31/21   85:7.7M
11/06/20  Codexis, Inc.                     10-Q        9/30/20   98:9.7M
 5/08/20  Codexis, Inc.                     10-Q        3/31/20   80:8.5M
11/06/19  Codexis, Inc.                     10-Q        9/30/19   82:10M
 8/06/19  Codexis, Inc.                     10-Q        6/30/19   77:10M
 6/21/19  Codexis, Inc.                     S-8         6/21/19    9:454K                                   Donnelley … Solutions/FA
 5/08/19  Codexis, Inc.                     10-Q        3/31/19   80:7.6M
 3/01/19  Codexis, Inc.                     10-K       12/31/18  102:13M
11/09/18  Codexis, Inc.                     10-Q        9/30/18   74:11M
 8/09/18  Codexis, Inc.                     10-Q        6/30/18   72:9.5M
 3/15/18  Codexis, Inc.                     10-K       12/31/17   89:10M
11/09/17  Codexis, Inc.                     10-Q        9/30/17   68:6.7M
 8/09/17  Codexis, Inc.                     10-Q        6/30/17   66:7M
11/08/16  Codexis, Inc.                     10-Q        9/30/16   65:5.7M
 8/09/16  Codexis, Inc.                     10-Q        6/30/16   62:5.3M
 3/08/16  Codexis, Inc.                     10-K       12/31/15   89:8.3M
 5/07/15  Codexis, Inc.                     10-Q        3/31/15   65:5.5M
11/06/14  Codexis, Inc.                     10-Q        9/30/14   76:9.6M
11/12/13  Codexis, Inc.                     10-Q        9/30/13   70:6.4M
 4/02/13  Codexis, Inc.                     10-K       12/31/12   94:15M                                    Workiva Inc.
11/07/12  Codexis, Inc.                     10-Q        9/30/12   68:5.1M                                   Donnelley … Solutions/FA
 9/04/12  Codexis, Inc.                     8-K:1,2,3,5 8/28/12    5:380K                                   Donnelley … Solutions/FA
 8/09/12  Codexis, Inc.                     10-Q        6/30/12    9:1.1M                                   Donnelley … Solutions/FA
 5/10/12  Codexis, Inc.                     10-Q        3/31/12   33:2.2M                                   Donnelley … Solutions/FA
 8/03/11  Codexis, Inc.                     10-Q        6/30/11   29:2.5M                                   Donnelley … Solutions/FA
 5/06/11  Codexis, Inc.                     10-Q        3/31/11    5:927K                                   Donnelley … Solutions/FA
11/04/10  Codexis, Inc.                     10-Q        9/30/10    5:820K                                   Donnelley … Solutions/FA
10/28/10  Codexis, Inc.                     8-K:1,2,9  10/28/10    4:463K                                   Donnelley … Solutions/FA
 5/28/10  Codexis, Inc.                     10-Q        3/31/10    6:850K                                   Donnelley … Solutions/FA
 3/31/10  Codexis, Inc.                     S-1/A                  9:3.7M                                   Donnelley … Solutions/FA
12/28/09  Codexis, Inc.                     S-1                   37:5.9M                                   Donnelley … Solutions/FA
Top
Filing Submission 0001200375-23-000012   –   Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)

Copyright © 2024 Fran Finnegan & Company LLC – All Rights Reserved.
AboutPrivacyRedactionsHelp — Tue., May 14, 4:07:21.2pm ET